The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: Data from the National Registry of Myocardial Infarction 2

Barron, Hal V.; Every, Nathan R.; Parsons, Lori; Angeja, Brad G.; Goldberg, Robert J.; Gore, Joel M.; Chou, Tony M.

doi:10.1067/mhj.2001.115295

Cited by 278 publications

(170 citation statements)

References 22 publications

Supporting

Mentioning

160

Contrasting

Unclassified

Order By: Relevance

“…[11][12][13][14][15][16][17] Multiple studies have suggested mortality benefits of IABP in patients with cardiogenic shock complicating AMI. 3,7,8,20,21 The American College of Cardiology (ACC) and the American Heart Association (AHA) recommend the use of IABP in patients with shock refractory to pharmacological therapy and as a stabilizing measure for urgent revascularization. 22 Nevertheless, the use of IABP in the treatment of cardiogenic shock remains remarkably low.…”

Section: Discussionmentioning

confidence: 99%

“…The method of diagnosis of AMI was as previously described (both ST-elevation myocardial infarction and non-ST-elevation myocardial infarction patients are included). 3 Patients were included in this analysis if they had cardiogenic shock or Killip class IV on initial presentation, or if cardiogenic shock developed during hospitalization with AMI (nϭ39 425). Cardiogenic shock was defined as "low blood pressure (Ͻ90 mm Hg) and signs of hypoperfusion (cool, clammy skin, oliguria, or altered sensorium), nonresponsive to fluid resuscitation or pressors" (Barron et al, 3 p 934).…”

Section: Patient and Data Collectionmentioning

confidence: 99%

“…3 Patients were included in this analysis if they had cardiogenic shock or Killip class IV on initial presentation, or if cardiogenic shock developed during hospitalization with AMI (nϭ39 425). Cardiogenic shock was defined as "low blood pressure (Ͻ90 mm Hg) and signs of hypoperfusion (cool, clammy skin, oliguria, or altered sensorium), nonresponsive to fluid resuscitation or pressors" (Barron et al, 3 p 934). Further analysis was then performed on the 750 hospitals in the registry that performed IABP and the 12 730 patients who underwent IABP treatment during their hospitalizations.…”

Section: Patient and Data Collectionmentioning

confidence: 99%

“…9,10 In the 23 180 patients in the National Registry of Myocardial Infarction 2 (NRMI-2) with cardiogenic shock, the use of IABP in conjunction with thrombolytic therapy decreased the odds of death by 18%. 3 The outcome of selected medical procedures is increasingly associated with hospital and operator volume, particularly in the setting of coronary artery bypass graft (CABG) surgery. 11,12 Recent studies have now confirmed that the mortality rate of patients undergoing percutaneous coronary interventions is similarly affected by hospital procedural volumes.…”

mentioning

confidence: 99%

“…[1][2][3] Before the modern reperfusion era, intra-aortic balloon counterpulsation (IABP) was shown to have favorable hemodynamic effects in patients with cardiogenic shock. 4,5 Although it appears that conventional fibrinolytic therapy alone is often unsuccessful, 6 in the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial, the use of IABP in patients undergoing reperfusion therapy led to a trend toward lower 30-day and 1-year mortality.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Relation Between Hospital Intra-Aortic Balloon Counterpulsation Volume and Mortality in Acute Myocardial Infarction Complicated by Cardiogenic Shock

et al. 2003

Self Cite

View full text Add to dashboard Cite

Background-Increasing evidence suggests an inverse relationship between outcome and the total number of invasive cardiac procedures performed at a given hospital. The purpose of the present study was to determine if a similar relationship exists between the number of intra-aortic balloon counterpulsation (IABP) procedures performed at a given hospital per year and the in-hospital mortality rate of patients with acute myocardial infarction complicated by cardiogenic shock. Methods and Results-We

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Patient and Data Collectionmentioning

confidence: 99%

Section: Patient and Data Collectionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Relation Between Hospital Intra-Aortic Balloon Counterpulsation Volume and Mortality in Acute Myocardial Infarction Complicated by Cardiogenic Shock

et al. 2003

Self Cite

View full text Add to dashboard Cite

show abstract

Intra-aortic Balloon Pump Therapy for Acute Myocardial Infarction

et al. 2015

View full text Add to dashboard Cite

IMPORTANCE Intra-aortic balloon pump (IABP) therapy is a widely used intervention for acute myocardial infarction with cardiogenic shock. Guidelines, which previously strongly recommended it, have recently undergone substantial change.OBJECTIVE To assess IABP efficacy in acute myocardial infarction.DATA SOURCES Human studies found in Pubmed, Embase, and Cochrane libraries through December 2014 and in reference lists of selected articles. Search strings were "myocardial infarction" or "acute coronary syndrome" and "intra-aortic balloon pump" or "counterpulsation."STUDY SELECTION Randomized clinical trials (RCTs) and observational studies comparing use of IABP with no IABP in patients with acute myocardial infarction. DATA EXTRACTION AND SYNTHESISTwo reviewers independently extracted the data, and risk of bias in RCTs was assessed using the Cochrane risk of bias tool. We conducted separate meta-analyses of the RCTs and observational studies. Data were quantitatively synthesized using random-effects meta-analysis. MAIN OUTCOMES AND MEASURES Thirty-day mortality.RESULTS There were 12 eligible RCTs randomizing 2123 patients. In the RCTs, IABP use had no statistically significant effect on mortality (odds ratio [OR], 0.96 [95% CI, 0.74-1.24]), with no significant heterogeneity among trials (I 2 = 0%; P = .52). This result was consistent when studies were stratified by the presence (OR, 0.94 [95% CI, 0.69-1.28]; P = .69, I 2 = 0%) or absence (OR, 0.98 [95% CI, 0.57-1.69]; P = .95, I 2 = 17%) of cardiogenic shock. There were 15 eligible observational studies totaling 15 530 patients. Their results were mutually conflicting (heterogeneity I 2 = 97%; P < .001), causing wide uncertainty in the summary estimate for the association with mortality (OR, 0.96 [95% CI, 0.54-1.70]). A simple index of baseline risk marker imbalance in the observational studies appeared to explain much of the heterogeneity in the observational data (R 2 meta = 46.2%; P < .001).CONCLUSIONS AND RELEVANCE Use of IABP was not found to improve mortality among patients with acute myocardial infarction in the RCTs, regardless of whether patients had cardiogenic shock. The observational studies showed a variety of mutually contradictory associations between IABP therapy and mortality, much of which was explained by the differences between studies in the balance of risk factors between IABP and non-IABP groups.

show abstract

Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock

Unverzagt¹,

Prondzinsky²,

Buerke³

et al. 2008

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: Data from the National Registry of Myocardial Infarction 2

Cited by 278 publications

References 22 publications

Relation Between Hospital Intra-Aortic Balloon Counterpulsation Volume and Mortality in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Relation Between Hospital Intra-Aortic Balloon Counterpulsation Volume and Mortality in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Intra-aortic Balloon Pump Therapy for Acute Myocardial Infarction

Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock

Contact Info

Product

Resources

About